---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-22-000080"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2022-07-08T23:59:59+00:00"
generated_at: "2026-06-24T18:03:16.412469+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics closes Phase 2 enoblituzumab study after 7 hemorrhagic fatalities in head and neck cancer

## Summary
- Phase 2 study CP-MGA271-06 closed due to 7 fatal hemorrhagic events among 62 SCCHN patients.
- 6 of 7 deaths assessed as unrelated to study treatment; 1 possibly related; incidence exceeded literature rate of 1–3.6%.
- Prior enoblituzumab studies in >340 patients had <1% fatal hemorrhage; nonclinical tox showed no coagulopathy.
- Company informed FDA and investigators; no new patients enrolled or treated as of July 7, 2022.
- Closure does not affect ongoing MGC018 ADC program; internal review and data analysis continue.

## SEC filing metadata
- accession: 0001125345-22-000080
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2022-07-08T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000080/0001125345-22-000080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534522000080/mgnx-20220708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-22-000080
- JSON: https://secwatch.observer/filing/0001125345-22-000080.json
- Plain text: https://secwatch.observer/filing/0001125345-22-000080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.